Northern Capital Management LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 46.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 52,552 shares of the company’s stock after purchasing an additional 16,560 shares during the period. Johnson & Johnson accounts for approximately 1.5% of Northern Capital Management LLC’s portfolio, making the stock its 6th biggest holding. Northern Capital Management LLC’s holdings in Johnson & Johnson were worth $6,377,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in JNJ. BlackRock Inc. raised its holdings in Johnson & Johnson by 4.7% in the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after buying an additional 7,853,141 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Johnson & Johnson by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock valued at $3,676,999,000 after buying an additional 541,338 shares during the period. Fisher Asset Management LLC raised its holdings in Johnson & Johnson by 3.8% in the 2nd quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock valued at $1,591,811,000 after buying an additional 478,982 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Johnson & Johnson by 4.5% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,978,198 shares of the company’s stock valued at $1,089,415,000 after buying an additional 387,504 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Johnson & Johnson by 9.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock valued at $967,793,000 after buying an additional 654,350 shares during the period. Institutional investors own 66.06% of the company’s stock.

In other news, CEO Alex Gorsky sold 264,465 shares of the business’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the completion of the transaction, the chief executive officer now directly owns 481,254 shares of the company’s stock, valued at $70,243,833.84. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 349,805 shares of company stock valued at $50,593,707. 0.22% of the stock is currently owned by corporate insiders.

JNJ has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday. Finally, Citigroup boosted their price objective on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $142.54.

NYSE JNJ opened at $147.73 on Tuesday. The stock has a market capitalization of $391.68 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 2.28 and a beta of 0.58. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.44.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. Johnson & Johnson’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.90 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.44%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

TRADEMARK VIOLATION NOTICE: “Northern Capital Management LLC Has $6.38 Million Holdings in Johnson & Johnson (JNJ)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2018/11/20/northern-capital-management-llc-has-6-38-million-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Float

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.